Mark Sulkowski, MD






Site Investigator

  • Vice-chair, Hepatitis TSG
  • Vice-Chair, Steering Committee of Hepatitis TSG (Dec 2014)
  • Member, HBV Cure Working Group of the HEP TSG (Mar 2015)
  • Co-Vice-Chair, NASH Focus Group of the ITSG/HEPTSG (April 2016)
  • Chair ACTG 5329
  • Co-chair ACTG 5334s
  • Investigator, ACTG 5335s


Leadership Committees

Clinical Trials

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More